<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084981</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01451</org_study_id>
    <secondary_id>NCI-2012-01451</secondary_id>
    <secondary_id>NCI-6237</secondary_id>
    <secondary_id>OSU-2003C0087</secondary_id>
    <secondary_id>OSU-0346</secondary_id>
    <secondary_id>CDR0000367115</secondary_id>
    <secondary_id>OSU 0346</secondary_id>
    <secondary_id>6237</secondary_id>
    <secondary_id>U01CA076576</secondary_id>
    <nct_id>NCT00084981</nct_id>
  </id_info>
  <brief_title>Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of decitabine and valproic acid&#xD;
      in treating patients with non-small cell lung cancer. Drugs used in chemotherapy, such as&#xD;
      decitabine and valproic acid, work in different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety and tolerability of decitabine and valproic acid in patients with&#xD;
      non-small cell lung cancer.&#xD;
&#xD;
      II. Determine the recommended phase II dose of this regimen in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the ability of this regimen to lead to biological changes in tumor and surrogate&#xD;
      tissues in these patients, including hypomethylation of target genes known to be methylated&#xD;
      in NSCLC (CDKN2, APC, BMP3B, CDH1 and RASSF1A) in biopsy specimens and surrogate tissues&#xD;
      (peripheral blood mononuclear cells [PBMC] and plasma/serum DNA); acetylation and methylation&#xD;
      changes in histones from tumor and surrogate tissues (PBMC and oral epithelial cells);&#xD;
      inhibition of histone deacetylase (HDAC) activity in peripheral blood; pharmacokinetic&#xD;
      analysis of Decitabine and Valproic Acid; DNA methyltransferase 1 (DNMT1) protein loss in&#xD;
      PBMC and buccal cells; response of hemoglobin F in patients with non-hematologic conditions&#xD;
      to DNMT and HDAC inhibition; and preliminary evidence of antitumor activity in non-small cell&#xD;
      lung cancer.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive decitabine IV over 1 hour on days 1-10 and oral valproic acid three times&#xD;
      daily on days 5-21. Treatment repeats every 28 days for 6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of decitabine and valproic acid until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. After the MTD is&#xD;
      determined, an additional 6 patients are treated at that dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD, defined as dose in which fewer than 1/3 or 2/6 patients experience DLT</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (decitabine, valproic acid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive decitabine IV over 1 hour on days 1-10 and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Cohorts of 3-6 patients receive escalating doses of decitabine and valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. After the MTD is determined, an additional 6 patients are treated at that dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (decitabine, valproic acid)</arm_group_label>
    <other_name>5-aza-dCyd</other_name>
    <other_name>5AZA</other_name>
    <other_name>DAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valproic acid</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (decitabine, valproic acid)</arm_group_label>
    <other_name>Alti-Valproic</other_name>
    <other_name>Depakene</other_name>
    <other_name>Novo-Valproic</other_name>
    <other_name>VA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (decitabine, valproic acid)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (decitabine, valproic acid)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer&#xD;
&#xD;
          -  Tumor accessible to biopsy by bronchoscopy, through surface biopsy (e.g., skin punch&#xD;
             biopsy for skin/subcutaneous metastasis) or through CT scan guidance&#xD;
&#xD;
          -  Not eligible for curative surgery, chemotherapy, radiotherapy, or multimodality&#xD;
             treatment options&#xD;
&#xD;
          -  No uncontrolled brain metastases&#xD;
&#xD;
               -  Controlled brain metastases allowed provided patient has no neurologic&#xD;
                  deterioration when off steroids; has completed prior radiotherapy or other&#xD;
                  treatments; has fully recovered from prior treatment; and does not require&#xD;
                  anticonvulsants&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  WBC &gt; 3,000/mm^3&#xD;
&#xD;
          -  AST and ALT =&lt; 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 times ULN&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance &gt;= 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior allergic reaction to compounds of similar chemical or biological composition&#xD;
             to decitabine, valproic acid, or other study agents&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No ongoing or active infection requiring antibiotics&#xD;
&#xD;
          -  No history of seizures requiring anticonvulsants&#xD;
&#xD;
          -  No medical problem that would preclude study participation&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other active malignancy except non-melanoma skin cancer or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  No concurrent prophylactic growth factors (e.g., filgrastim [G-CSF] or epoetin alfa)&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  Prior definitive radiotherapy to the chest allowed&#xD;
&#xD;
               -  Clinical (radiographic or other) evidence of tumor progression for previously&#xD;
                  irradiated indicator lesion in the chest&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
          -  Prior curative or palliative intent surgery allowed&#xD;
&#xD;
          -  At least 2 weeks since prior surgery and recovered&#xD;
&#xD;
          -  At least 4 weeks since prior photodynamic therapy&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent administration of any of the following medications:&#xD;
&#xD;
               -  Aspirin&#xD;
&#xD;
                    -  Chronic low-dose (=&lt; 81 mg/day) aspirin allowed&#xD;
&#xD;
               -  Felbamate&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Amitriptyline&#xD;
&#xD;
               -  Nortriptyline&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Clonazepam&#xD;
&#xD;
               -  Diazepam&#xD;
&#xD;
               -  Ethosuximide&#xD;
&#xD;
               -  Lamotrigine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Barbiturates&#xD;
&#xD;
               -  Primidone&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Zidovudine&#xD;
&#xD;
          -  No concurrent divalproex sodium&#xD;
&#xD;
          -  Concurrent gabapentin for neuropathic pain allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Otterson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>September 27, 2013</last_update_submitted>
  <last_update_submitted_qc>September 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

